Samsung Biologics has signed an agreement to purchase 100 percent of Swiss CDMO PolyPeptide Group for 2.7 trillion won through a controlling stake purchase and public tender offer. The transaction, scheduled for completion by December, represents the largest acquisition in South Korea's biopharmaceutical sector. All verified details derive from Yonhap News reporting.